Optiscan adds $5M tranche for glucose monitor
Optiscan Biomedical, developer of a less-invasive human glucose monitor for hospitals, received an additional $5 million in a second round of funding that now totals $53 million. The boost came from Wexford Capital, reports VentureWire.
The Hayward, Calif.-based company plans to use its new resources to see its product through clinical trials next year. While it has already been tested on humans, it has yet to receive the stamp of approval from the Food and Drug… Continue Reading
Life sciences briefing: Thursday, Nov. 29, 2007
Featured companies: Adenosine Therapeutics, Allylix, Caprotec BioAnalytics, Equipois, F-Star, Insightec, MedNets.com, Renal Solutions, Transport Pharmaceuticals, VeriCare Management
UPDATED: Expanded items on Transport Pharmaceuticals, InSightec and VeriCare Management.
Transport Pharma aims for $35M for cold-sore treatment — Framingham, Mass.-based Transport Pharmaceuticals, a dermatology-focused biotech developing a new treatment for cold sores, is looking to raise $35 million in a fifth funding round, VentureWire reports (subscription required). Hillman Co., Quaker BioVentures, Carlyle Group and EGS Healthcare Capital Partners have pledged $15… Continue Reading
Jazz Pharmaceuticals files for gutsy $172M IPO
Jazz Pharmaceuticals, a Palo Alto, Calif. company that seeks to license drugs from other companies, buy other drug companies and develop its own drugs, all in the area neurology and psychiatry, has filed for a $172.5 million IPO.
Here is its filing. It is four years old, and lost $81 million last year.
This is largely a financial engineering strategy, and it will be interesting to see whether the public is willing to buy stock in such… Continue Reading